After doing some more reading into this, it's net price in the US is 51k or so, it sounds like insurance negotiated it down a lot.  

India is a special case where they aren't using the actual drug, its special generic formula that allows the cost to be significantly lower.  This is in conjunction with 8.7 million people in India with chronic Hep C. The price per treatment becomes significantly less.

Cost for drug development is only going to become more expensive unless there is a paradigm shift in them finding the right molecule formulation out of the millions of possibilities. There isn't a good fix for the cost of R&D.